CONF-2025-ObesityWeek-REDEFINE-Sessions — ObesityWeek 2025 + ADA 2025: REDEFINE CagriSema Presentations
[DRAFT — authored 2026-04-19. Conference context web-verified via ADA, Novo Nordisk press releases, and HCPLive coverage 2026-04-19.]
Scope Note
The REDEFINE program was presented across two conferences in 2025. This note captures both venues because faculty and learners may encounter either as the "conference source":
Venue 1 — ADA 85th Scientific Sessions (June 2025)
- Conference: American Diabetes Association 85th Scientific Sessions
- Dates: June 20-23, 2025
- Presentation date: June 22, 2025, 8:00 AM CT
- Presenters (joint session): Timothy Garvey, MD (REDEFINE-1) and Melanie Davies, MD (REDEFINE-2)
- Simultaneous publication: New England Journal of Medicine (June 21, 2025) — both REDEFINE-1 and REDEFINE-2 published
Venue 2 — ObesityWeek 2025 (November 2025)
- Conference: ObesityWeek 2025 (The Obesity Society annual meeting)
- Dates: November 4-7, 2025
- Location: Atlanta, GA, USA
- Additional REDEFINE-program sessions:
- REDEFINE-5 (CagriSema in East Asian adults with overweight/obesity) — oral presentation, Wed Nov 5, 4:00-4:15 PM ET, presented by Ishigaki
- REDEFINE-1 post-hoc analyses: cardiovascular risk reduction potential; proportion achieving clinically relevant treatment targets (BMI, waist-to-height ratio)
Key Findings Summary (across both venues)
REDEFINE-1 (non-T2D obesity, n=3,417)
- CagriSema 2.4 mg + 2.4 mg: -20.4% body weight at week 68
- Placebo: -3.0%
- Cagrilintide 2.4 mg alone: -11.5%
- Semaglutide 2.4 mg alone: -14.9%
- Note: the NEJM REDEFINE-1 publication reports the four-arm trial; the −22.7% figure commonly cited in summaries is from a specific analytic subset. The ObesityWeek 2025 coverage reported -20.4% for the primary CagriSema arm.
REDEFINE-2 (T2D + obesity, n=1,206)
- CagriSema: -13.7% body weight at week 68
- Placebo: -3.4%
- Superiority demonstrated vs semaglutide 2.4 mg active comparator
REDEFINE-5 (East Asian adults, ObesityWeek 2025)
- CagriSema efficacy in East Asian population — primary results presented at ObesityWeek 2025; full publication pending as of April 2026
Cross-Links to Full Publications
- DOI-10-1056-NEJMoa2502081 – REDEFINE-1 CagriSema Obesity — Garvey WT et al. NEJM 2025;392(25):2445-2456
- PMID-40544432 – REDEFINE-2 CagriSema vs Semaglutide — Davies MJ et al. NEJM 2025
Relevance to Module 5
- Lesson 5.4 (Pipeline Peptides Section 2) — REDEFINE program is the primary Phase 3 evidence for CagriSema
- CagriSema profile PubMed Research section
Sources
- ADA CagriSema press release
- Pharmacy Times ADA 2025 coverage
- HCPLive "Diabetes Dialogue: REDEFINE 1 and REDEFINE 2" with Garvey and Davies
- Novo Nordisk ObesityWeek 2025 press release
- Novo Nordisk REDEFINE-5 slide deck (ObesityWeek 2025)
Orchestrator Notes
- CONF note cross-linked to full-publication DOI/PMID notes.
- Two venues documented because the REDEFINE program was presented at both ADA (June 2025) and ObesityWeek (November 2025).
- Verified 2026-04-19.
Tags
#conference #obesityweek #obesityweek25 #ada-scientific-sessions #ada25 #cagrisema #redefine #cagrilintide #semaglutide